• Technical Use of HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-06-24

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus provides a robust solution for synthesizing high-yield, randomly Cy3-labeled RNA probes suitable for fluorescence-based research, particularly in situ hybridization and Northern blot applications. It is not validated for diagnostic, therapeutic, or clinical workflows and should only be used where fluorescent RNA detection is required.

• Refining In Vitro Drug Response Evaluation in Cancer Researc

  2026-06-23

  Schwartz's dissertation introduces improved in vitro methods to distinguish drug-induced cell death from proliferation arrest, highlighting the significance of measuring both relative and fractional viability. These insights offer cancer researchers enhanced resolution in evaluating anti-cancer compounds’ effects, with implications for optimizing angiogenesis inhibition assays and translational pipeline accuracy.

• Resiniferatoxin: Strategic Mechanisms Driving Translational

  2026-06-23

  This article explores resiniferatoxin (RTX) as a mechanistically precise and ultra-potent TRPV1 agonist, clarifying its action in pain research and its translational value. It synthesizes mechanistic insights, protocol guidance, competitive positioning, and recent evidence—particularly the use of RTX in TRPV1-targeted models—to empower translational researchers seeking to innovate in neuropathic and osteoarthritis pain. The discussion is rooted in recent advances and identifies how RTX's unique pharmacology elevates both preclinical and emerging clinical workflows.

• Marein Reverses ABCG2-Mediated Mitoxantrone Resistance in Ca

  2026-06-22

  The referenced study demonstrates that marein, a flavonoid from Coreopsis tinctoria, restores chemosensitivity in multidrug-resistant cancer cells by competitively inhibiting the ABCG2 transporter. This mechanistic insight offers a promising strategy for overcoming resistance to topoisomerase II inhibitors such as Mitoxantrone, with direct relevance to optimizing combination therapies in oncology research.

• AZD3463 ALK/IGF1R Inhibitor: Advanced Neuroblastoma Protocol

  2026-06-22

  AZD-3463, an advanced ALK/IGF1R inhibitor, enables robust neuroblastoma research through dual pathway blockade and synergy with chemotherapeutics. This article delivers actionable setup guidance, protocol parameters, and troubleshooting strategies that maximize the translational impact of APExBIO's AZD-3463 in ALK-driven cancer models.

• AAL-993: Pushing the Boundaries of Precision VEGF Inhibition

  2026-06-21

  Explore how AAL-993, a potent VEGF receptor inhibitor, enables next-generation anti-angiogenic research. This article offers novel insight into optimizing tumor angiogenesis assays and integrating recent network pharmacology findings for advanced oncology modeling.

• HATU in Modern Peptide Design: Mechanistic Precision and Nex

  2026-06-20

  Explore how HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) is transforming peptide synthesis chemistry through advanced mechanism-driven strategies. This article delivers unique, research-grounded insights into optimizing carboxylic acid activation and amide bond formation for drug discovery.

• Bispecific Anti-M1R/B6R Antibodies Advance Orthopoxvirus Pro

  2026-06-19

  The reference study systematically characterizes monoclonal antibodies targeting MPXV immunogens M1R and B6R, and demonstrates that bispecific antibody formats can provide robust, broad-spectrum protection against orthopoxviruses. These findings highlight new avenues for therapeutic antibody development and offer important benchmarks for translational immunology and virology research.

• AZD3463: Mechanistic Leverage for Translational Neuroblastom

  2026-06-19

  Explore how AZD3463, a potent ALK/IGF1R inhibitor, strategically empowers translational researchers to dissect and therapeutically target the PI3K/AKT/mTOR axis in neuroblastoma. This article blends deep mechanistic insight, protocol guidance, and competitive context, while connecting recent signaling crosstalk findings in oncology to the next wave of precision therapeutics.

• Improving In Vitro Evaluation of Cancer Drug Responses

  2026-06-18

  Schwartz's dissertation challenges standard in vitro drug evaluation by distinguishing growth inhibition from cell death, introducing dual-metric analysis for greater precision. These innovations enhance the reliability of assessing agents like Tivozanib in preclinical oncology research.

• Pazopanib (GW-786034) in Precision Oncology: Beyond Angiogen

  2026-06-18

  Explore how Pazopanib (GW-786034) is redefining cancer research models through nuanced targeting of RTK pathways and ATRX-deficient tumors. This article unpacks advanced mechanistic insights and practical assay guidance for translational studies.

• Pazopanib (GW-786034): Translational Strategies for ATRX-Def

  2026-06-17

  Explore how Pazopanib (GW-786034) advances cancer research by targeting angiogenesis and tumor growth, with a unique focus on ATRX-deficient models. This in-depth article delivers practical protocol guidance and actionable insights beyond standard reviews.

• DDX23 Restricts SVA via Caspase-Mediated Apoptosis: Mechanis

  2026-06-17

  This study elucidates how DEAD-box helicase 23 (DDX23) restricts Senecavirus A (SVA) replication by targeting viral proteins for caspase-dependent degradation, while SVA counters with its 2B and 3A proteins to degrade DDX23. By pinpointing critical amino acid residues, the research details a molecular 'arms race' and highlights potential targets for antiviral intervention in swine virology.

• Tivozanib (AV-951): Selective VEGFR Inhibition in Oncology R

  2026-06-16

  Tivozanib (AV-951) is a potent and highly selective tyrosine kinase inhibitor targeting VEGFR-1, VEGFR-2, and VEGFR-3. It demonstrates superior anti-angiogenic efficacy and selectivity in renal cell carcinoma models compared to earlier TKIs. This article details its molecular mechanism, validated benchmarks, and workflow integration for advanced oncology research.

• Refining In Vitro Evaluation of Anti-Cancer Drug Responses

  2026-06-16

  Schwartz's dissertation challenges common in vitro drug testing by dissecting how anti-cancer agents influence both cell proliferation and death, rather than treating these outcomes interchangeably. The work advances experimental design and analysis, enabling more precise interpretation of angiogenesis inhibition and tumor growth modulation in cancer biology research.

7498 records 15/500 page Previous Next First page 上5页 1112131415 下5页 Last page